At the news
? NEUTRALIMPACT 2/10 144 filed May 13, 2026 at 10:34 ET
Director Michael Thomas Henderson filed a Form 144 on May 13, 2026, indicating intent to sell 60,000 shares of Apogee Therapeutics common stock, with an approximate market value of $4.95 million based on the filing date price. This is a routine insider sale by a director, not a C-suite officer, and the shares appear to originate from RSU vesting, reducing its signaling significance.
- Director Michael Thomas Henderson filed Form 144 to sell 60,000 shares.
- Estimated sale value ~$4.95 million based on filing date market price.
- Shares acquired via RSU vesting from October 2023 through January 2024.
- Henderson is a director, not CEO/CFO, reducing insider signal weight.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access